PBMs sidestep the Senate’s tough questions — but lawmakers hint at legislation
The middlemen escaped largely unscathed from their congressional grilling Tuesday — but there are hints that lawmakers will soon pursue legislation to open up the industry.
WASHINGTON — The much-maligned pharmacy middlemen escaped largely unscathed during a high-profile congressional hearing Tuesday — but the powerful bipartisan duo behind the hearing now appears intent on legislating, and it looks like increasing transparency will be their primary goal.
Executives for the country’s five largest pharmacy benefit managers, the middlemen that negotiate with drug makers over the price of their drugs, were expected to face hard questions about their role in the
